menu
    • menu
    [{"orgOrder":0,"company":"Voronoi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VRN101099","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Voronoi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voronoi \/ Inapplicable"},{"orgOrder":0,"company":"Voronoi","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Voronoi","amount2":0.62,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"Undisclosed","sponsorNew":"Voronoi \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Voronoi \/ ORIC Pharmaceuticals"},{"orgOrder":0,"company":"Voronoi","sponsor":"METiS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Voronoi","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Voronoi \/ METiS Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Voronoi \/ METiS Therapeutics"},{"orgOrder":0,"company":"Voronoi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VRN110755","moa":"EGFR C797S | EGFR L858R | EGFR T790M | EGFR-Ex19del","graph1":"Undisclosed","graph2":"Phase I","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Voronoi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Voronoi \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Voronoi

    Menu

    Voronoi

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRN110755

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Food & Proton Pump Inhibitor on Pharmacokinetics of VRN110755

                            Details : VRN110755 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : VRN110755

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRN101099

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of VRN101099 in Patients With HER2-Positive Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : VRN101099

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : METiS Therapeutics

                            Deal Size : $482.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi

                            Details : Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program worldwide.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $1.7 million

                            September 13, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : METiS Therapeutics

                            Deal Size : $482.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Voronoi

                            South Korea arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORIC-114

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : ORIC Pharmaceuticals

                            Deal Size : $621.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Oric Pharma Teams up With Korean firm to Expand Precision Oncology Pipeline

                            Details : ORIC secured exclusive rights worldwide excluding the People’s Republic of China, Hong Kong, Macau and Taiwan (the ORIC Territory) for the development and commercialization of ORIC-114.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $5.0 million

                            October 19, 2020

                            Lead Product(s) : ORIC-114

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : ORIC Pharmaceuticals

                            Deal Size : $621.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth